Conference Details - Overview
Current Trends in Genitourinary Malignancies
The Westin Pasadena
Pasadena, CA
October 31, 2009
Conference Overview
CME-Certified Symposium
The Current Trends in Genitourinary Malignancies regional symposium is designed to provide state-of-the-art information on the clinical management of bladder, kidney, and prostate cancers. Current concepts in chemotherapeutic and multimodality approaches to the treatment of all stages of bladder cancer will be presented with an emphasis on practical clinical context to facilitate integration into practice. The latest insights into the biologic basis of the pathogenesis of renal cell carcinoma and trial data pertaining to the use of first- and second-generation targeted agents will be presented. Experts will discuss relevant data for the selection of appropriate therapy for individual patients with advanced kidney cancer in multiple settings. Data on the molecular elements of prostate cancer and the clinical management of patients with PSA relapse and high-risk localized disease will be covered. Participants will review available clinical data concerning conventional chemotherapy, hormonal therapy, novel targeted and combination therapy, and immunotherapy for the treatment of advanced and hormone-refractory prostate cancer. In addition, this symposium will include updates on relevant ongoing clinical trials evaluating new therapeutic regimens for the treatment of the different genitourinary malignancies. This interactive symposium will include didactic sessions, case-based learning, and panel discussions with leading faculty who will offer their opinions regarding the clinical challenges practicing physicians face today.
The purpose of this activity is to inform participants of the latest advances in the treatment of genitourinary malignancies and to promote their integration into the practice setting as well as to describe future directions in research and clinical trials.
Additional CME Accreditation and Credit Designation Information
Registered Nurse: The California Board of Registered Nursing accepts AMA PRA Category 1 Credits™ toward license renewal. On the BRN license renewal form, report the number of hours you attended (up to 6 hours of credit) and fill in “CME Category 1” for the provider number.
California AB 1195: This activity complies with California Assembly Bill 1195, signed November 2005, requiring continuing medical education courses with patient care components to include curricula in the subject of cultural and linguistic competency. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area.
This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, urologists, internal medicine and primary care physicians, and basic research investigators interested in the treatment and management of patients with kidney, bladder, and prostate cancers. Fellows, oncology nurses, oncology physician assistants, and pharmacists interested in the treatment of genitourinary malignancies are also invited to attend.At the conclusion of this symposium, you should be able to:
- Assess the current state of prostate cancer screening and prevention with regard to patient characteristics
- Discuss the role of androgen receptors and genetic defects in the progression of prostate cancer
- Integrate current state-of-the-art concepts for multimodality treatment, including hormonal therapy, chemotherapy, radiation therapy, and surgery, into the management of patients with localized and high-risk prostate cancer
- Explain the biologic basis underlying the predisposition of prostate cancer to metastasize to bone and discuss the use of bone-targeted therapeutic agents
- Apply appropriate taxane-based chemotherapy to the management of hormone-refractory prostate cancer
- Evaluate the role of emerging agents including immunotherapy, cytotoxic agents that inhibit the cell cycle, and novel agents that target the tumor vasculature or the endothelin signaling system in the treatment of hormone-refractory prostate cancer
- Evaluate and integrate state-of-the-art management of superficial, invasive, and metastatic bladder cancer, including surgical options and chemotherapy regimens, in the neoadjuvant, adjuvant, and advanced disease settings
- Assess emerging treatment options, including cytotoxic and targeted agents, for localized and advanced bladder cancer
- Describe the underlying biologic basis of the pathogenesis of renal cell carcinoma
- Incorporate current standards into the surgical management of patients with small/localized kidney cancers
- Integrate appropriate antiangiogenic therapies, such as multitargeted kinase inhibitors and mTOR inhibitors, into the treatment of advanced renal cell carcinoma based on patient characteristics and prior therapy
- Appraise the current status of sequential versus combination therapy options for advanced renal cell carcinoma
- Select appropriate patients for enrollment on clinical trials